您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SB1317
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SB1317
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SB1317图片
CAS NO:937270-47-8
规格:98%
分子量:372.46
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
CDK,JAK and FLT inhibitor
CAS:937270-47-8
分子式:C23H24N4O
分子量:372.46
纯度:98%
存储:Store at -20°C

Background:

SB1317 is a potent inhibitor of Cyclin dependent kinases (CDKs), FMS-like tyrosine kinase-3 (FLT3) and Janus kinase 2 (JAK2) with IC50 values of 13nM, 56nM and 73nM for CDK2, JAK2 and FLT3, respectively [1].
CDKs are serine-threonine kinases that regulating the cell cycle. JAK2 is a nonreciprocal intracellular tyrosine kinase that transduces cytokine-mediated signals via the JAK-STAT pathway. FLT3 is a cytokine receptor and plays an important role in the normal development of haematopoietic stem cells [1].
In luciferase-expressing MM1S cells, SB1317 overcame the proliferative/protective advantage conferred by IL-6. In MM1S cells, SB1317 increased the percentage of cells in G2/M phases and decreased cells in the S phase. Also, SB1317 increased the amount of cells in the subG0 region [2].
In CB17-SCID mice bearing human multiple myeloma plasmacytoma xenograft models (the bortezomib-sensitive MM1S model and the more bortezomib-resistant OPM2 model), SB1317 significantly inhibited tumor growth [2]. In a subcutaneous AML model, treatment mice with SB1317 dosed 10, 20 or 40 mg/kg daily for 21 days reduced the average tumor volume by 53%, 61% and 113%, respectively [3].
参考文献:
[1]. William AD, Lee AC, Goh KC, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem, 2012, 55(1): 169-196.
[2]. Álvarez-Fernández S, Ortiz-Ruiz MJ, Parrott T, et al. Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res, 2013, 19(10): 2677-2687.
[3]. Goh KC, Novotny-Diermayr V, Hart S, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia, 2012, 26(2): 236-243.